Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors

Rossana Berardi, Mariangela Torniai, Sara Pusceddu, Francesca Spada, Toni Ibrahim, Maria Pia Brizzi, Lorenzo Antonuzzo, Piero Ferolla, Francesco Panzuto, Nicola Silvestris, Stefano Partelli, Benedetta Ferretti, Federica Freddari, Calogero Gucciardino, Enrica Testa, Laura Concas, Sabina Murgioni, Alberto Bongiovanni, Clizia Zichi, Nada RivaMaria Rinzivillo, Oronzo Brunetti, Lucio Giustini, Francesco Di Costanzo, Gianfranco Delle Fave, Nicola Fazio, Filippo De Braud, Massimo Falconi, Stefano Cascinu

Research output: Contribution to journalArticle

Abstract

The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 females, median age 55 years) with advanced PNETs were treated with everolimus for ≥3 months. According to a Receiver operating characteristics (ROC) analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and toxicity were comparable in the two groups. However, patients in group A experienced more dose modifications than patients in group B. Median OS was 24 months in Group A while in Group B it was not reached (HR: 26.9; 95% CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/day experienced a significantly longer OS and experienced a trend to higher response rate. Overall, our study results showed that both CD and DI of everolimus play a prognostic role for patients with advanced PNETs treated with everolimus. This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions.

Original languageEnglish
Pages (from-to)1493-1499
Number of pages7
JournalCancer Medicine
Volume6
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Neuroendocrine Tumors
Everolimus
ROC Curve
Survival

Keywords

  • Everolimus
  • mTOR inhibitor
  • pancreatic neuroendocrine tumors
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. / Berardi, Rossana; Torniai, Mariangela; Pusceddu, Sara; Spada, Francesca; Ibrahim, Toni; Brizzi, Maria Pia; Antonuzzo, Lorenzo; Ferolla, Piero; Panzuto, Francesco; Silvestris, Nicola; Partelli, Stefano; Ferretti, Benedetta; Freddari, Federica; Gucciardino, Calogero; Testa, Enrica; Concas, Laura; Murgioni, Sabina; Bongiovanni, Alberto; Zichi, Clizia; Riva, Nada; Rinzivillo, Maria; Brunetti, Oronzo; Giustini, Lucio; Di Costanzo, Francesco; Delle Fave, Gianfranco; Fazio, Nicola; De Braud, Filippo; Falconi, Massimo; Cascinu, Stefano.

In: Cancer Medicine, Vol. 6, No. 7, 01.07.2017, p. 1493-1499.

Research output: Contribution to journalArticle

Berardi, R, Torniai, M, Pusceddu, S, Spada, F, Ibrahim, T, Brizzi, MP, Antonuzzo, L, Ferolla, P, Panzuto, F, Silvestris, N, Partelli, S, Ferretti, B, Freddari, F, Gucciardino, C, Testa, E, Concas, L, Murgioni, S, Bongiovanni, A, Zichi, C, Riva, N, Rinzivillo, M, Brunetti, O, Giustini, L, Di Costanzo, F, Delle Fave, G, Fazio, N, De Braud, F, Falconi, M & Cascinu, S 2017, 'Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors', Cancer Medicine, vol. 6, no. 7, pp. 1493-1499. https://doi.org/10.1002/cam4.1028
Berardi, Rossana ; Torniai, Mariangela ; Pusceddu, Sara ; Spada, Francesca ; Ibrahim, Toni ; Brizzi, Maria Pia ; Antonuzzo, Lorenzo ; Ferolla, Piero ; Panzuto, Francesco ; Silvestris, Nicola ; Partelli, Stefano ; Ferretti, Benedetta ; Freddari, Federica ; Gucciardino, Calogero ; Testa, Enrica ; Concas, Laura ; Murgioni, Sabina ; Bongiovanni, Alberto ; Zichi, Clizia ; Riva, Nada ; Rinzivillo, Maria ; Brunetti, Oronzo ; Giustini, Lucio ; Di Costanzo, Francesco ; Delle Fave, Gianfranco ; Fazio, Nicola ; De Braud, Filippo ; Falconi, Massimo ; Cascinu, Stefano. / Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. In: Cancer Medicine. 2017 ; Vol. 6, No. 7. pp. 1493-1499.
@article{41234c45139b440bbf8dcbf90bc20320,
title = "Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors",
abstract = "The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 females, median age 55 years) with advanced PNETs were treated with everolimus for ≥3 months. According to a Receiver operating characteristics (ROC) analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and toxicity were comparable in the two groups. However, patients in group A experienced more dose modifications than patients in group B. Median OS was 24 months in Group A while in Group B it was not reached (HR: 26.9; 95{\%} CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/day experienced a significantly longer OS and experienced a trend to higher response rate. Overall, our study results showed that both CD and DI of everolimus play a prognostic role for patients with advanced PNETs treated with everolimus. This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions.",
keywords = "Everolimus, mTOR inhibitor, pancreatic neuroendocrine tumors, targeted therapy",
author = "Rossana Berardi and Mariangela Torniai and Sara Pusceddu and Francesca Spada and Toni Ibrahim and Brizzi, {Maria Pia} and Lorenzo Antonuzzo and Piero Ferolla and Francesco Panzuto and Nicola Silvestris and Stefano Partelli and Benedetta Ferretti and Federica Freddari and Calogero Gucciardino and Enrica Testa and Laura Concas and Sabina Murgioni and Alberto Bongiovanni and Clizia Zichi and Nada Riva and Maria Rinzivillo and Oronzo Brunetti and Lucio Giustini and {Di Costanzo}, Francesco and {Delle Fave}, Gianfranco and Nicola Fazio and {De Braud}, Filippo and Massimo Falconi and Stefano Cascinu",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/cam4.1028",
language = "English",
volume = "6",
pages = "1493--1499",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors

AU - Berardi, Rossana

AU - Torniai, Mariangela

AU - Pusceddu, Sara

AU - Spada, Francesca

AU - Ibrahim, Toni

AU - Brizzi, Maria Pia

AU - Antonuzzo, Lorenzo

AU - Ferolla, Piero

AU - Panzuto, Francesco

AU - Silvestris, Nicola

AU - Partelli, Stefano

AU - Ferretti, Benedetta

AU - Freddari, Federica

AU - Gucciardino, Calogero

AU - Testa, Enrica

AU - Concas, Laura

AU - Murgioni, Sabina

AU - Bongiovanni, Alberto

AU - Zichi, Clizia

AU - Riva, Nada

AU - Rinzivillo, Maria

AU - Brunetti, Oronzo

AU - Giustini, Lucio

AU - Di Costanzo, Francesco

AU - Delle Fave, Gianfranco

AU - Fazio, Nicola

AU - De Braud, Filippo

AU - Falconi, Massimo

AU - Cascinu, Stefano

PY - 2017/7/1

Y1 - 2017/7/1

N2 - The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 females, median age 55 years) with advanced PNETs were treated with everolimus for ≥3 months. According to a Receiver operating characteristics (ROC) analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and toxicity were comparable in the two groups. However, patients in group A experienced more dose modifications than patients in group B. Median OS was 24 months in Group A while in Group B it was not reached (HR: 26.9; 95% CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/day experienced a significantly longer OS and experienced a trend to higher response rate. Overall, our study results showed that both CD and DI of everolimus play a prognostic role for patients with advanced PNETs treated with everolimus. This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions.

AB - The aim of this work is to assess if cumulative dose (CD) and dose intensity (DI) of everolimus may affect survival of advanced pancreatic neuroendocrine tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 females, median age 55 years) with advanced PNETs were treated with everolimus for ≥3 months. According to a Receiver operating characteristics (ROC) analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and toxicity were comparable in the two groups. However, patients in group A experienced more dose modifications than patients in group B. Median OS was 24 months in Group A while in Group B it was not reached (HR: 26.9; 95% CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/day experienced a significantly longer OS and experienced a trend to higher response rate. Overall, our study results showed that both CD and DI of everolimus play a prognostic role for patients with advanced PNETs treated with everolimus. This should prompt efforts to continue everolimus administration in responsive patients up to at least 3000 mg despite delays or temporary interruptions.

KW - Everolimus

KW - mTOR inhibitor

KW - pancreatic neuroendocrine tumors

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85019934316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019934316&partnerID=8YFLogxK

U2 - 10.1002/cam4.1028

DO - 10.1002/cam4.1028

M3 - Article

AN - SCOPUS:85019934316

VL - 6

SP - 1493

EP - 1499

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 7

ER -